The meetings were set up by some 2,100 companies with 4,300 delegates. But who are these 2,100 companies and with whom are the delegates meeting? Could looking at this behind the scenes data, in the "Trenches of Business Development", reveal something about deal making to come in the next 12 months? We went into the back end of the system to analyze the data, and provide the results here: 2010 BIO Business Forum Partnering Results. (This was presented as part of the Campbell Alliance Super Session last Wednesday. To view the slides from the Campbell Alliance presentation on their survey of 156 Business Development executives, click here: The Campbell Alliance Dealmaker's Intentions Survey - pdf )
The analysis in this slide deck (slides 9 & 10 in particular) is focused on 1) only drug biotech, 2) unpartnered lead compounds, 3) clinical trials, 4) only in the 11 disease areas discussed in the Campbell Alliance survey results, and 5) only meetings with "PHARMA". Thus, all the CRO meetings and out-licensor to out-licensor meetings are excluded. By "PHARMA" we include any in-licensor, thus all large biotechs and specialty pharmas that intend to bring products in-house or fund a partnership. Genetic disorders, renal failure, urology, opthamology, and certain other diseases are not included for continuity with the Campbell study, reducing the number of potential drug companies analyzed by over 20%.